Your browser is no longer supported. Please, upgrade your browser.
RPRX Repros Therapeutics Inc. monthly Stock Chart
RPRX [NASD]
Repros Therapeutics Inc.
Index- P/E- EPS (ttm)-1.27 Insider Own0.50% Shs Outstand24.27M Perf Week-20.59%
Market Cap19.66M Forward P/E- EPS next Y-0.96 Insider Trans38.41% Shs Float24.19M Perf Month-22.86%
Income-30.80M PEG- EPS next Q-0.27 Inst Own49.10% Short Float4.18% Perf Quarter-49.69%
Sales- P/S- EPS this Y-1.50% Inst Trans-14.76% Short Ratio1.49 Perf Half Y-90.54%
Book/sh0.99 P/B0.82 EPS next Y20.70% ROA-85.30% Target Price2.75 Perf Year-90.64%
Cash/sh1.08 P/C0.75 EPS next 5Y27.90% ROE-91.80% 52W Range0.80 - 10.05 Perf YTD-33.06%
Dividend- P/FCF- EPS past 5Y26.00% ROI- 52W High-91.74% Beta-0.31
Dividend %- Quick Ratio10.60 Sales past 5Y- Gross Margin- 52W Low3.76% ATR0.10
Employees27 Current Ratio10.60 Sales Q/Q- Oper. Margin- RSI (14)36.01 Volatility10.42% 11.04%
OptionableYes Debt/Eq0.00 EPS Q/Q15.60% Profit Margin- Rel Volume0.22 Prev Close0.81
ShortableYes LT Debt/Eq0.00 EarningsMar 14 BMO Payout- Avg Volume678.76K Price0.83
Recom2.70 SMA20-14.95% SMA50-28.70% SMA200-84.19% Volume35,389 Change2.48%
Oct-30-15Downgrade BofA/Merrill Neutral → Underperform
May-14-13Reiterated Ascendiant Capital Markets Strong Buy $19 → $23
Mar-28-13Reiterated Ladenburg Thalmann Buy $18 → $25
Nov-15-12Reiterated Ascendiant Capital Markets Strong Buy $12 → $18
Oct-09-12Reiterated Ladenburg Thalmann Buy $15 → $18
Apr-10-12Initiated Ascendiant Capital Markets Strong Buy $6
Mar-16-11Reiterated Ladenburg Thalmann Buy $6 → $9
Feb-09-16 04:30PM  Repros, FDA Meet to Discuss Issues of Enclomiphene's CRL
Feb-08-16 04:09PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -12.62%
04:01PM  Repros Holds Meeting With FDA to Discuss Complete Response Letter for Enclomiphene in the Treatment of Secondary Hypogonadism GlobeNewswire
Jan-19-16 11:22AM  Smart Money Highlights Oversold Stocks in Small Cap Biotechs Accesswire -6.06%
Jan-11-16 09:16AM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
09:15AM  Repros Announces Court of Appeals Affirmation of Summary Judgment in Favor of the Company GlobeNewswire
Jan-06-16 04:21PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers -5.51%
Jan-04-16 04:06PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits +7.44%
04:05PM  Repros Updates Enclomiphene Program GlobeNewswire
Dec-22-15 04:25PM  Repros Provides Update on Proellex Program, Data by 3Q16
Dec-21-15 04:07PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
04:05PM  Repros Updates Proellex® Program GlobeNewswire
Dec-09-15 01:50PM  Is Evolution Petroleum Corporation (EPM) Going to Burn These Hedge Funds? at Insider Monkey
Dec-08-15 01:17PM  REPROS THERAPEUTICS INC. Financials
Dec-03-15 09:30AM  The Zacks Analyst Blog Highlights: Repros Therapeutics, AbbVie, Amgen, XOMA and Gilead
Dec-02-15 04:25PM  Repros Hits 52-Week Low after Enclomiphene Receives CRL
02:09PM  Biotech Stock Roundup: Repros Tanks on CRL, AbbVie Multiple Myeloma Drug Approved
Dec-01-15 01:42PM  Repros (RPRX) Stock Plummets After FDA Rejects Hypogonadism Drug Trial Results at TheStreet -27.50%
09:51AM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure
09:50AM  Repros Therapeutics Receives Complete Response Letter From FDA for Enclomiphene GlobeNewswire
Nov-30-15 08:00AM  Repros Therapeutics (RPRX) Looks Good: Stock Soars 45.1% -5.51%
Nov-29-15 03:30PM  4 Stocks Under $10 to Trade for Big Breakouts at TheStreet
Nov-27-15 01:36PM  Why Repros Therapeutics Inc (RPRX) Was One Of Black Fridays Biggest Gainers at Insider Monkey +45.14%
09:30AM  The Zacks Analyst Blog Highlights: BioMarin, Amgen, Vertex, Gilead, Biogen and Repros
Nov-25-15 10:15AM  Biotech Stock Roundup: KaloBios Soars as Shkreli Steps In, FDA Panel Not Convinced about BioMarin Drug
Nov-17-15 04:10PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure
Nov-16-15 11:09AM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers
Nov-13-15 04:30PM  Repros Provides Update on Phase IIb Study on Proellex
Nov-12-15 04:09PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure
04:05PM  Repros Therapeutics Completes Randomization of Phase 2b Study of Vaginal Proellex(R) in Women With Symptomatic Uterine Fibroid Bleeding GlobeNewswire
Nov-10-15 11:00AM  Repros' Q3 Loss Narrower than Expected, Pipeline in Focus
Nov-09-15 10:47AM  Repros' (RPRX) Q3 Loss a Penny Narrower than Expected -6.74%
09:25AM  Repros Therapeutics reports 3Q loss
09:16AM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition
09:15AM  Repros Therapeutics Inc.(R) Reports Third Quarter 2015 Financial Results GlobeNewswire
Nov-05-15 03:50PM  What's in Store for Repros (RPRX) this Earnings Season? -9.42%
09:30AM  The Zacks Analyst Blog Highlights: AbbVie, Amgen, Dyax, Repros and Gilead
Nov-04-15 10:41AM  Biotech Stock Roundup: AbbVie's Humira Remains Strong, Shire to Buy Dyax +6.11%
Nov-03-15 09:10AM  How The 'Low T' Wars Cast A Shadow Over Repros' Testosterone Alternative at Forbes +7.78%
Nov-01-15 09:10AM  4 Key FDA Decisions Expected in November and December at 24/7 Wall St.
Oct-30-15 11:20AM  Repros Hits 52-Week Low, FDA Delays Enclomiphene Meeting -17.79%
Oct-29-15 04:09PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure -55.56%
03:12PM  Repros Therapeutics Announces Cancellation of FDA Advisory Committee Meeting to Review Enclomiphene for the Treatment of Secondary Hypogonadism GlobeNewswire
Oct-28-15 09:57AM  Biotech Stock Roundup: Biogen Tops Estimates, FDA Approves Alexion's Strensiq
Oct-15-15 04:00PM  LPCN: Files NDA for LPCN 1021 with FDA Approval on Track for 2016
Sep-29-15 09:52AM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure
Aug-13-15 08:10PM  10-Q for Repros Therapeutics, Inc. at Company Spotlight
Aug-11-15 10:30AM  Repros Incurs Narrower Y/Y Loss in Q2, Pipeline in Focus - Analyst Blog
Aug-10-15 10:33AM  Repros (RPRX) Reports Narrower Y/Y Loss in Q2 - Tale of the Tape +6.91%
09:30AM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition
09:22AM  Repros Therapeutics reports 2Q loss
09:15AM  Repros Therapeutics Inc.(R) Reports Second Quarter 2015 Financial Results GlobeNewswire
Aug-07-15 02:40PM  What to Expect from Repros (RPRX) this Earnings Season? - Analyst Blog
Jul-09-15 01:58PM  3 Stocks Under $10 Triggering Breakout Trades at TheStreet
Jun-18-15 02:31PM  3 Biotech Stocks Under $10 to Trade for Breakouts at TheStreet
Jun-09-15 04:40PM  Repros' Enclomiphene to Face FDA Advisory Panel in November - Analyst Blog
06:03AM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure
Jun-08-15 05:48PM  Repros Announces Date of FDA Advisory Committee Review of NDA GlobeNewswire
Jun-01-15 04:17PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders
May-10-15 08:11PM  10-Q for Repros Therapeutics, Inc. at Company Spotlight
May-08-15 04:03PM  Repros Reports Narrower Y/Y Loss in Q1, Pipeline in Focus - Analyst Blog
May-07-15 04:15PM  What's in Store for Repros (RPRX) this Earnings Season? - Analyst Blog
11:18AM  Repros Therapeutics reports 1Q loss
09:16AM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition
09:15AM  Repros Therapeutics Inc.(R) Reports First Quarter 2015 Financial Results GlobeNewswire
May-04-15 08:12PM  10-K for Repros Therapeutics, Inc. at Company Spotlight
Apr-15-15 05:24PM  Repros Announces November 30, 2015 PDUFA Goal Date for New Drug Application at noodls
04:03PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure
04:01PM  Repros Announces November 30, 2015 PDUFA Goal Date for New Drug Application GlobeNewswire
Apr-13-15 01:27PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Other Events
Apr-08-15 08:56AM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure
Apr-07-15 02:50PM  Repros Gets EU Update on Secondary Hypogonadism Drug - Analyst Blog
Apr-06-15 04:20PM  Repros Receives Confirmation of Eligibility for Submission of a Centralized Marketing Authorization Application to the European Medicines Agency as a New Active Substance at noodls -5.07%
04:02PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure
04:01PM  Repros Receives Confirmation of Eligibility for Submission of a Centralized Marketing Authorization Application to the European Medicines Agency as a New Active Substance GlobeNewswire
Apr-02-15 05:24PM  Repros' Secondary Hypogonadism Drug Under FDA Review - Analyst Blog
04:27PM  Lumber Liquidators, CarMax are big market movers
Apr-01-15 05:06PM  Repros shares rally on testicle-stimulation drug application at MarketWatch
04:36PM  Repros Announces Acceptance for Filing of NDA at noodls
04:02PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure
04:01PM  Repros Announces Acceptance for Filing of NDA GlobeNewswire
Mar-16-15 10:33AM  Repros (RPRX) Incurs Narrower-than-Expected Loss in Q4 - Tale of the Tape
10:11AM  Repros Therapeutics Inc.(R) Reports Fourth Quarter and Year End 2014 Financial Results at noodls
09:48AM  Repros Therapeutics reports 4Q loss
09:17AM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Results of Operations and Financial Condition
09:15AM  Repros Therapeutics Inc.(R) Reports Fourth Quarter and Year End 2014 Financial Results GlobeNewswire
Mar-11-15 05:58PM  Will Repros (RPRX) Miss Estimates This Earnings Season? - Analyst Blog
Feb-26-15 01:18PM  5 Stocks Under $10 to Trade for Breakouts: SouFun, Repros and More at TheStreet
Feb-10-15 04:49PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Change in Directors or Principal Officers
Feb-03-15 06:15PM  Repros Files for Androxal in the U.S. for Hypogonadism - Analyst Blog
Feb-02-15 09:32AM  Repros Submits New Drug Application to FDA for Androxal (R) at noodls
09:16AM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure
09:15AM  Repros Submits New Drug Application to FDA for Androxal (R) GlobeNewswire
Jan-12-15 09:02AM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure
Dec-29-14 04:44PM  Repros Initiates Two Phase 2B Uterine Fibroid Studies at noodls +6.71%
04:25PM  Energy Spinoffs Transocean Partners, Seventy Seven Energy Tumble at TheStreet
04:19PM  REPROS THERAPEUTICS INC. Files SEC form 8-K, Regulation FD Disclosure EDGAR Online
04:15PM  Repros Updates Androxal(R) Global Regulatory Status GlobeNewswire
04:15PM  Repros Initiates Two Phase 2B Uterine Fibroid Studies GlobeNewswire
09:15AM  Court Rules Inventors Correctly Named on Androxal(R) Patents GlobeNewswire
Repros Therapeutics Inc., a biopharmaceutical company, focuses on the development of new drugs to treat hormonal and reproductive system disorders for male and female in the United States. Its product portfolio includes Androxal, an oral therapy, which is in Phase III clinical trials for the treatment of low testosterone due to secondary hypogonadism; and Proellex that is in Phase IIB clinical trials for the treatment of symptoms associated with uterine fibroids, as well as in Phase II clinical trial for the treatment of endometriosis. The company has a license agreement with the National Institutes of Health to develop and commercialize Proellex. Repros Therapeutics Inc. was founded in 1987 and is based in The Woodlands, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Anderson KatherineChief Financial OfficerJan 27Buy1.0812,00012,96023,875Jan 28 04:12 PM
Wernicke J. F.Chief Medical OfficerJan 25Buy1.1110,00011,12610,000Jan 28 04:12 PM
PODOLSKI JOSEPHPresident and CEOJan 07Buy1.143,5003,99077,422Jan 07 04:44 PM
PODOLSKI JOSEPHPresident and CEOJan 06Buy1.208,1779,80473,922Jan 07 04:44 PM